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aeruginosa identified during the Steroids for
Corneal Ulcers Trial show elevated resistance to
fluoroquinolones
Durga S Borkar1, Nisha R Acharya1,2,5, Chelsia Leong3, Prajna Lalitha4, Muthiah Srinivasan4, Catherine E Oldenburg2,
Vicky Cevallos2, Thomas M Lietman1,2,5, David J Evans3,6 and Suzanne M J Fleiszig3,7*Abstract
Background: To determine the relationship between type three secretion genotype and fluoroquinolone resistance
for P. aeruginosa strains isolated from microbial keratitis during the Steroids for Corneal Ulcers Trial (SCUT) and for
two laboratory strains, PA103 and PAO1.
Methods: Confirmed P. aeruginosa isolates from the SCUT were divided into exoU(+) or exoU(−). The exoU(+) strains
contained the gene encoding ExoU, a powerful phospholipase toxin delivered into host cells by the type three
secretion system. Isolates were then assessed for susceptibility to fluoroquinolone, cephalosporin, and
aminoglycoside antibiotics using disk diffusion assays. Etest was used to determine the MIC of moxifloxacin and
other fluoroquinolones. Laboratory isolates in which the exoU gene was added or deleted were also tested.
Results: A significantly higher proportion of exoU(+) strains were resistant to ciprofloxacin (p = 0.001), gatifloxacin
(p = 0.003), and ofloxacin (p = 0.002) compared to exoU(−) isolates. There was no significant difference between
exoU(+) or exoU(−) negative isolates with respect to susceptibility to other antibiotics except gentamicin. Infections
involving resistant exoU(+) strains trended towards worse clinical outcome. Deletion or acquisition of exoU in
laboratory isolates did not affect fluoroquinolone susceptibility.
Conclusions: Fluoroquinolone susceptibility of P. aeruginosa isolated from the SCUT is consistent with previous
studies showing elevated resistance involving exoU encoding (cytotoxic) strains, and suggest worse clinical
outcome from infections involving resistant isolates. Determination of exoU expression in clinical isolates of
P. aeruginosa may be helpful in directing clinical management of patients with microbial keratitis.
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Pseudomonas aeruginosa is a leading cause of bacterial
keratitis involving contact lens wear or ocular injury
[1-5]. While the pathogenesis of P. aeruginosa keratitis
is complex, studies with in vivo models have shown that
the type three secretion system (T3SS) is a significant
contributor to disease pathogenesis [6-8]. Similar results* Correspondence: fleiszig@berkeley.edu
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nia [9], and expression of the T3SS is associated with
worse patient outcomes in ventilator-associated pneumo-
nia and bacteremia [10,11]. Other clinical studies have also
shown poor patient outcomes from P. aeruginosa infec-
tions are also associated with antimicrobial drug resist-
ance [12,13], a long recognized trait of this opportunistic
pathogen [14].
The T3SS effector ExoU is a potent phospholipase that
is cytotoxic towards host cells [15,16]. Several studies
have shown that the exoU gene is selected for in clinical
isolates from microbial keratitis [17-19], especially inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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other studies have also shown a relationship between
exoU expression and resistance of P. aeruginosa to con-
tact lens disinfectants [21], and to multiple antimicro-
bials [22], especially fluoroquinolones [23]. In the latter
instance, it was shown that P. aeruginosa clinical isolates
encoding exoU were more likely to encode multiple mu-
tations in quinolone target genes, e.g. gyrA and parC,
and suggested a co-evolution of these traits [24].
The Steroids for Corneal Ulcers Trial (SCUT), was
a randomized controlled trial investigating the effects
of adjunctive corticosteroid therapy to fluoroquinolone
(moxifloxacin) treatment on the outcomes of bacterial
keratitis [25,26]. Analysis of moxifloxacin resistance of
bacterial keratitis isolates (including P, aeruginosa) from
the SCUT study showed that increased resistance to this
fluoroquinolone in vitro (i.e. increased minimum inhibi-
tory concentration) was associated with poorer clinical
outcomes, including reduced visual acuity at 3 weeks, a
larger ulcer, and slower corneal re-epithelialization [27].
Here, we analyzed P. aeruginosa strains isolated from
the SCUT study, and two laboratory isolates and their
T3SS mutants, for their in vitro susceptibility to fluoro-
quinolones and other antimicrobials including cephalo-
sporins and aminoglycosides. Antimicrobial classes and
individual agents tested were chosen because of their
common clinical empirical use against bacterial keratitis
[28]. The objective was to determine if the SCUT clinical
isolates and laboratory strains of P. aeruginosa also
showed a relationship between fluoroquinolone resist-
ance and exoU expression.
Methods
a) Clinical and laboratory isolates of P. aeruginosa and
T3SS mutants
The P. aeruginosa isolates used were obtained from the
Steroids for Corneal Ulcers Trial (SCUT), a randomized
controlled trial investigating the effect of adjunctive
corticosteroids on outcomes in bacterial keratitis [25].
The SCUT study was conducted with the approval of
the University of California, San Francisco; Aravind Eye
Hospital, Madurai, India; Dartmouth-Hitchcock Medical
Center, Hanover, NH. Informed consent was obtained
from all study participants. Corneal isolates were collected
from patients with culture-confirmed bacterial keratitis.
The isolates used in the present study were previously
confirmed as P. aeruginosa using growth morphology,
Gram stain, and API test strips, and their type three secre-
tion gene profile was determined [29]. Presence of exoU
was determined by polymerase chain reaction using
primers and conditions described in detail by Ledbetter
et al. [30]. Two wild-type laboratory strains of P. aerugi-
nosa (PA103, encodes exoU) and PAO1 (does not en-
code exoU) were tested. For strain PA103, two T3SSmutants PA103exsA::Ω and PA103ΔexoU were also used.
Strain PAO1 was complemented with a plasmid encoding
exoU (pUCPexoU) or a plasmid control (pUCP18).
b) Antibiotic susceptibility testing
Susceptibility to moxifloxacin, the fluoroquinolone anti-
biotic used in the SCUT, was measured using the Etest
method (AB BIODISK, Solna, Sweden) for all isolates
using a standardized inoculum of 1 × 108 CFU/mL on
Mueller-Hinton agar plates, which were then incubated
at 35°C. Disc diffusion susceptibility testing was per-
formed for various other antibiotics (other fluoroqui-
nolones, cephalosporins, and aminoglycosides) and P.
aeruginosa strains classified as susceptible, intermedi-
ate, or resistant to each antibiotic tested based on the
Clinical and Laboratory Standards Institute (CLSI) guide-
lines [31]. Since CLSI guidelines do not provide sus-
ceptibility ranges for the MIC of moxifloxacin for P.
aeruginosa, susceptibility ranges for ciprofloxacin were
used for Etest results. Laboratory personnel were masked
as to P. aeruginosa strain identity. Laboratory isolates
were tested after the conclusion of the SCUT using similar
methods, which have been described previously [25]. An
ATCC P. aeruginosa strain (ATCC 27853) was used for
quality control when performing antibiotic susceptibility
testing for laboratory strains.
c) Visual acuity
SCUT patients with culture-confirmed bacterial keratitis
were evaluated at multiple time points, including enroll-
ment and three months, by certified refractionists who
performed visual acuity examinations. Visual acuity was
measured as best spectacle-corrected visual acuity (BSCVA)
in logMAR units, with 0.1 logMAR corresponding to
approximately one line of acuity. Laboratory personnel
were masked to the clinical data.
d) Statistical analysis
Differences in disc diffusion susceptibility for various
antibiotics, and mean minimum inhibitory concentration
(MIC) of moxifloxacin, between exoU(+) or exoU(−)
strain types were compared using Fisher’s exact test and
the Student’s t-Test, respectively. The t-Test was also
used to compare the change in BSCVA between enroll-
ment and three months between patients with corneal
ulcers caused by resistant or non-resistant exoU(+) P.
aeruginosa.
Results
Of 500 patients enrolled in the SCUT, 110 had a corneal
ulcer involving P. aeruginosa [32]. Confirmed P. aerugi-
nosa isolates that were available for study were divided
into two groups according to presence or absence of the
exoU gene. Table 1 shows disc diffusion antimicrobial
Table 1 Antibiotic susceptibility1 of SCUT Isolates of P. aeruginosa and T3SS genotype
exoU(+) (n = 19) exoU(-) (n = 75) P-value2
Resistant Non-resistant Resistant Non-resistant
Fluoroquinolones
Ciprofloxacin3 5 (28%) 13 (72%) 1 (1%) 74 (99%) 0.001
Gatifloxacin 5 (26%) 14 (74%) 2 (3%) 73 (97%) 0.003
Ofloxacin 6 (32%) 13 (68%) 3 (4%) 72 (96%) 0.002
Cephalosporins
Cefotaxime 3 (16%) 16 (84%) 9 (12%) 66 (88%) 0.70
Ceftazidime 3 (16%) 16 (84%) 5 (7%) 70 (93%) 0.20
Aminoglycosides
Amikacin 1 (5%) 18 (95%) 1 (1%) 74 (99%) 0.37
Gentamicin 5 (26%) 14 (74%) 4 (5%) 71 (95%) 0.02
Tobramycin 3 (16%) 16 (84%) 2 (3%) 73 (97%) 0.054
1Disc diffusion assay.
2Fisher’s exact test.
3Disc diffusion susceptibility data for ciprofloxacin not available for one exoU(+) isolate (n = 18).
Figure 1 Minimum inhibitory concentration (MIC) of moxifloxacin
for P. aeruginosa clinical isolates with or without the exoU gene.
The median for each group is represented by the line in the middle of
each box. The interquartile range (IQR), the span of the 25th to 75th
percentiles, is denoted by the lower and upper bounds of each box,
respectively. The whiskers extend from the smallest MIC within 1.5 ×
IQR below the 25th percentile to the largest MIC within 1.5 × IQR
above the 75th percentile. Individual data points denote values outside
this range. Note that 3 additional isolates were identified and included
compared to disk diffusion assay data; 2 were exoU(+) and 1 was
exoU(−). The P-value displayed was obtained by two-group mean-
comparison t-Test of the log, in base 2, of the MIC. The average MIC
shown for each subgroup is the mean of the log, in base 2, of the
MIC transformed to MIC in micrograms/ml.
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lates. A significantly higher proportion of exoU(+) strains
were resistant to ciprofloxacin (p = 0.001), gatifloxacin
(p = 0.003), and ofloxacin (p = 0.002) compared to exoU(−)
isolates. There was no significant difference between exoU
(+) or exoU(−) negative isolates with respect to suscepti-
bility to the cephalosporins tested, or to the aminoglyco-
sides amikacin and tobramycin. Interestingly, there were
significantly more gentamicin resistant exoU(+) isolates
(p = 0.02).
Of the 19 exoU(+) corneal isolates, 4 were resistant to
gatifloxacin, ciprofloxacin, and ofloxacin based on disc
diffusion susceptibility testing, and had an MIC greater
than or equal to 4 micrograms/ml. The BSCVA of pa-
tients with ulcers caused by the resistant ExoU(+) iso-
lates improved, on average, approximately six lines less
from enrollment compared to patients with ulcers caused
by non-resistant ExoU(+) isolates (−0.38 logMAR vs. -1.04
logMAR) although this difference was not statistically
significant (p = 0.08).
In another set of experiments, the MIC of moxifloxa-
cin was determined and compared for 21 exoU(+) and
76 exoU(−) SCUT isolates of P. aeruginosa. Figure 1
shows that isolates encoding exoU had, on average, a
greater than two-fold higher MIC compared to exoU(−)
strains (p = 0.0001).
Laboratory isolates of P. aeruginosa were also tested to
determine if genetic deletion of the T3SS, or deletion or
acquisition of exoU, affected bacterial susceptibility to
fluoroquinolones or other antibiotics using disc diffusion
and Etest assays (Table 2). Neither deletion of the T3SS
or exoU in the cytotoxic strain PA103, nor acquisition of
exoU in the invasive strain PAO1, affected sensitivity to
any antimicrobial tested.Discussion
Topical fluoroquinolones are commonly used in the
treatment of bacterial keratitis, in which P. aeruginosa is
a leading causative pathogen. The data presented in this
study show the antimicrobial resistance patterns of P.
aeruginosa strains (94) isolated from patients during the
Table 2 Antibiotic susceptibility testing results for P. aeruginosa laboratory isolates
Disc diffusion susceptibility1 Etest2
Strain Cipro Gati Oflox Ceftaz Gent Tob Moxi Moxi
PA103 S S S S S S S S (1.0)
PA103 exsA::Ω S S S S S S S S (0.5)
PA103 ΔexoU S S S S S S S S (0.5)
PAO1 S S S S S S S S (0.5)
PAO1 + pUCP exoU S S S S S S S S (0.5)
PAO1 + pUCP18 S S S S S S S S (1.0)
ATCC 27853 (QC) S S S S S S I I (2.0)
1S = Sensitive; I = Intermediate; R = Resistant. Ranges used to determine susceptibility were taken from the Clinical and Laboratory Standards Institute guidelines.
QC = Quality Control.
2S = Sensitive; I = Intermediate; R = Resistant. Numbers in parentheses represent the MIC (micrograms/ml).
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number of isolates resistant to fluoroquinolones if the
bacteria encode the type three secreted cytotoxin ExoU.
The data also confirm that deletion or acquisition of
exoU gene does not affect fluoroquinolone susceptibility.
These data are consistent with previous studies showing
an association of exoU expression with fluoroquinolone
resistance in P. aeruginosa, and support the hypothesis
that T3SS expression and fluoroquinolone resistance are
co-selected traits in both ocular and non-ocular clinical
isolates [22,23]. Indeed, prior studies have found a sig-
nificantly higher rate of gyrA mutations, combined with
mutations in other fluoroquinolone target genes e.g.
parC, in exoU encoding P. aeruginosa isolates [23,24].
It was of interest that we also found significantly more
gentamicin resistant exoU(+) isolates in the study, al-
though this did not occur for other aminoglycosides.
This finding is consistent with a previous study looking
at bacteremia isolates of P. aeruginosa in which the pres-
ence of exoU was also associated with increased resist-
ance to gentamicin, but not amikacin [11]. It would be
of interest to determine if gentamicin resistance in these
ocular exoU(+) isolates relates to specific mutations in
drug target genes, as shown for fluoroquinolones [24].
In bacterial keratitis, antibiotic susceptibility likely
plays a role in clinical outcome, suggesting a role for
testing antibiotic susceptibility in management deci-
sions [27,33]. Interestingly, we found that SCUT pa-
tients with ulcers caused by fluoroquinolone resistant
exoU(+) P. aeruginosa isolates trended toward worse
visual outcomes at three months compared to those
with ulcers caused by non-resistant exoU(+) isolates.
These results could reflect increased bacterial persist-
ence in the cornea, allowing for greater tissue damage
from bacterial toxins (including ExoU), and from host
immune infiltrative responses.
The continuing emergence of antimicrobial resistant
strains has the potential to influence “optimal” treatmentof P. aeruginosa keratitis. However, P. aeruginosa resist-
ance rates to fluoroquinolones and aminoglycosides, com-
mon choices for management of this condition, remain
relatively low and stable in many places, although they can
vary widely by geographical location and time [22,34-36].
Our study, and those of others [11,22-24], however, sug-
gest that the combination of exoU and antibiotic resist-
ance may be particularly deleterious to the patient and
rapid identification of these isolates, if possible, could help
optimize treatment.
Conclusion
Fluoroquinolone susceptibility of P. aeruginosa isolated
from the SCUT is consistent with previous studies
showing elevated resistance involving exoU encoding
(cytotoxic) strains, and suggest worse clinical outcome
from infections involving these resistant isolates. In-
creased gentamicin resistance is also associated with
exoU(+) strains. Determination of exoU expression in
clinical isolates of P. aeruginosa, and antibiotic suscepti-
bility testing, may be helpful in directing optimal clin-
ical management of patients with microbial keratitis if
methods could be developed with sufficient speed and
accuracy, and which could be applied in a clinical
setting.
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